1. Home
  2. EU vs TRDA Comparison

EU vs TRDA Comparison

Compare EU & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.24

Market Cap

306.9M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.66

Market Cap

275.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
TRDA
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
275.3M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
EU
TRDA
Price
$1.24
$7.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.00
$21.00
AVG Volume (30 Days)
3.4M
231.2K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
N/A
N/A
Revenue
$43,155,000.00
$25,421,000.00
Revenue This Year
$212.11
$39.97
Revenue Next Year
$29.88
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$5.02
52 Week High
$4.19
$16.45

Technical Indicators

Market Signals
Indicator
EU
TRDA
Relative Strength Index (RSI) 49.88 57.46
Support Level $1.03 $5.71
Resistance Level $1.47 $7.95
Average True Range (ATR) 0.09 0.42
MACD 0.00 -0.01
Stochastic Oscillator 43.62 86.41

Price Performance

Historical Comparison
EU
TRDA

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: